In orthotopic osteosarcoma models lacking fusions, pharmacologic TrkA blockade dampened NGF-induced MMP-2 programs and reduced metastatic spread, consistent with the NGF/MMP axis observed in patient and cell-based datasets (90, 91). The gene discussed is MMP2; the disease is osteosarcoma.